| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 67 | 2022 | 306 | 13.150 |
Why?
|
| Polysaccharides | 40 | 2022 | 176 | 11.790 |
Why?
|
| Biomarkers, Tumor | 28 | 2021 | 508 | 5.300 |
Why?
|
| Glycoproteins | 22 | 2022 | 238 | 4.920 |
Why?
|
| Prostatic Neoplasms | 26 | 2021 | 778 | 4.310 |
Why?
|
| Proteomics | 24 | 2022 | 246 | 3.570 |
Why?
|
| Glycomics | 11 | 2021 | 29 | 3.310 |
Why?
|
| Paraffin Embedding | 11 | 2021 | 47 | 3.260 |
Why?
|
| Tissue Fixation | 8 | 2021 | 58 | 3.020 |
Why?
|
| Glycosylation | 31 | 2022 | 185 | 2.710 |
Why?
|
| Proteome | 16 | 2022 | 87 | 2.700 |
Why?
|
| Protein Processing, Post-Translational | 9 | 2021 | 284 | 2.440 |
Why?
|
| Mass Spectrometry | 19 | 2022 | 284 | 2.380 |
Why?
|
| Neoplasm Proteins | 9 | 2020 | 307 | 2.130 |
Why?
|
| Prostate | 11 | 2021 | 116 | 1.950 |
Why?
|
| Molecular Imaging | 6 | 2021 | 45 | 1.930 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2020 | 110 | 1.790 |
Why?
|
| Thymidine Kinase | 13 | 2002 | 18 | 1.730 |
Why?
|
| Breast Neoplasms | 11 | 2022 | 1536 | 1.700 |
Why?
|
| Formaldehyde | 9 | 2021 | 48 | 1.680 |
Why?
|
| Liver Neoplasms | 10 | 2022 | 334 | 1.680 |
Why?
|
| Pancreatic Neoplasms | 7 | 2020 | 332 | 1.530 |
Why?
|
| Blood Proteins | 8 | 2011 | 94 | 1.510 |
Why?
|
| Carcinoma, Hepatocellular | 8 | 2021 | 163 | 1.500 |
Why?
|
| Humans | 146 | 2022 | 68618 | 1.490 |
Why?
|
| Kidney | 9 | 2020 | 945 | 1.460 |
Why?
|
| Kidney Neoplasms | 5 | 2020 | 206 | 1.430 |
Why?
|
| Extracellular Matrix | 8 | 2021 | 493 | 1.420 |
Why?
|
| Peptides | 6 | 2021 | 455 | 1.320 |
Why?
|
| Neoplasms | 8 | 2017 | 1667 | 1.290 |
Why?
|
| Affinity Labels | 31 | 2008 | 66 | 1.250 |
Why?
|
| Herpesvirus 1, Human | 8 | 2002 | 30 | 1.220 |
Why?
|
| Azides | 18 | 2013 | 56 | 1.210 |
Why?
|
| Bacterial Typing Techniques | 3 | 2012 | 19 | 1.200 |
Why?
|
| Animals | 74 | 2022 | 20881 | 1.200 |
Why?
|
| Trypsin | 5 | 2018 | 64 | 1.130 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 4 | 2020 | 14 | 1.110 |
Why?
|
| Collagen | 6 | 2021 | 636 | 1.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2020 | 46 | 1.050 |
Why?
|
| Lectins | 3 | 2020 | 81 | 1.030 |
Why?
|
| Exosomes | 3 | 2018 | 44 | 1.020 |
Why?
|
| Ganciclovir | 10 | 2002 | 27 | 1.000 |
Why?
|
| Glycoside Hydrolases | 3 | 2022 | 25 | 0.920 |
Why?
|
| Biomarkers | 14 | 2022 | 1593 | 0.920 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2021 | 689 | 0.910 |
Why?
|
| Disease Progression | 10 | 2020 | 1038 | 0.880 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 756 | 0.860 |
Why?
|
| Amino Sugars | 2 | 2019 | 12 | 0.820 |
Why?
|
| Gene Expression Profiling | 7 | 2018 | 498 | 0.800 |
Why?
|
| Carbohydrates | 2 | 2013 | 57 | 0.790 |
Why?
|
| Diagnostic Imaging | 2 | 2021 | 201 | 0.760 |
Why?
|
| Fixatives | 1 | 2021 | 24 | 0.750 |
Why?
|
| Glucuronosyltransferase | 11 | 2006 | 38 | 0.720 |
Why?
|
| Proteins | 5 | 2017 | 474 | 0.710 |
Why?
|
| Glycosyltransferases | 8 | 1998 | 13 | 0.690 |
Why?
|
| Uridine Diphosphate Glucuronic Acid | 10 | 1997 | 16 | 0.690 |
Why?
|
| Workflow | 5 | 2021 | 100 | 0.690 |
Why?
|
| Liver | 18 | 2022 | 1118 | 0.680 |
Why?
|
| Male | 59 | 2022 | 37321 | 0.670 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 47 | 0.660 |
Why?
|
| Microsomes, Liver | 9 | 1999 | 44 | 0.640 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2019 | 41 | 0.630 |
Why?
|
| Brain | 5 | 2021 | 2176 | 0.630 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 3 | 2021 | 67 | 0.630 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 129 | 0.620 |
Why?
|
| Acetylglucosamine | 2 | 2020 | 46 | 0.610 |
Why?
|
| Ceramides | 5 | 2022 | 578 | 0.610 |
Why?
|
| Transcriptome | 2 | 2017 | 164 | 0.610 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2020 | 144 | 0.610 |
Why?
|
| Breast | 1 | 2018 | 137 | 0.600 |
Why?
|
| Mice | 28 | 2022 | 8474 | 0.600 |
Why?
|
| Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase | 5 | 2022 | 17 | 0.590 |
Why?
|
| Protein Array Analysis | 6 | 2012 | 32 | 0.580 |
Why?
|
| Uridine Diphosphate Glucose | 14 | 1996 | 19 | 0.560 |
Why?
|
| Fibroblasts | 1 | 2021 | 902 | 0.540 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 1070 | 0.530 |
Why?
|
| Immunohistochemistry | 9 | 2021 | 1174 | 0.530 |
Why?
|
| Heart Valves | 1 | 2017 | 171 | 0.510 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 6 | 2018 | 201 | 0.490 |
Why?
|
| Staphylococcus aureus | 3 | 2012 | 175 | 0.490 |
Why?
|
| Sphingolipids | 4 | 2018 | 337 | 0.470 |
Why?
|
| Glucosyltransferases | 9 | 1996 | 28 | 0.460 |
Why?
|
| Simplexvirus | 6 | 2002 | 26 | 0.460 |
Why?
|
| Semen | 2 | 2014 | 29 | 0.450 |
Why?
|
| Female | 37 | 2022 | 38074 | 0.450 |
Why?
|
| Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 4 | 2022 | 19 | 0.440 |
Why?
|
| Colonic Neoplasms | 4 | 2016 | 299 | 0.440 |
Why?
|
| Biomedical Research | 1 | 2016 | 310 | 0.440 |
Why?
|
| Prostate-Specific Antigen | 3 | 2013 | 138 | 0.440 |
Why?
|
| Signal Transduction | 5 | 2021 | 2689 | 0.430 |
Why?
|
| Zidovudine | 3 | 1998 | 27 | 0.430 |
Why?
|
| Stromal Cells | 1 | 2013 | 113 | 0.420 |
Why?
|
| Substrate Specificity | 14 | 2021 | 234 | 0.420 |
Why?
|
| Molecular Sequence Data | 17 | 2014 | 1447 | 0.410 |
Why?
|
| Tissue Array Analysis | 5 | 2020 | 53 | 0.410 |
Why?
|
| Lipids | 1 | 2014 | 298 | 0.410 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2009 | 56 | 0.410 |
Why?
|
| Cell Line, Tumor | 13 | 2020 | 1851 | 0.410 |
Why?
|
| Middle Aged | 27 | 2022 | 21147 | 0.400 |
Why?
|
| Glycosphingolipids | 3 | 2017 | 51 | 0.390 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2008 | 629 | 0.380 |
Why?
|
| Aortic Valve | 3 | 2021 | 249 | 0.370 |
Why?
|
| Isomerism | 2 | 2021 | 63 | 0.370 |
Why?
|
| Head and Neck Neoplasms | 2 | 2008 | 561 | 0.370 |
Why?
|
| Genetic Therapy | 4 | 2002 | 291 | 0.370 |
Why?
|
| Amino Acid Sequence | 12 | 2020 | 1083 | 0.360 |
Why?
|
| Prostatic Diseases | 2 | 2012 | 5 | 0.360 |
Why?
|
| Linear Energy Transfer | 1 | 2010 | 2 | 0.360 |
Why?
|
| Neuraminidase | 3 | 2022 | 36 | 0.360 |
Why?
|
| Carbohydrate Conformation | 5 | 2021 | 25 | 0.360 |
Why?
|
| Bacterial Proteins | 1 | 2012 | 245 | 0.350 |
Why?
|
| Cell Movement | 5 | 2018 | 630 | 0.350 |
Why?
|
| Data Mining | 1 | 2010 | 45 | 0.350 |
Why?
|
| Enzymes, Immobilized | 1 | 2009 | 11 | 0.340 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 1293 | 0.340 |
Why?
|
| Uridine | 5 | 2000 | 8 | 0.340 |
Why?
|
| Liver Cirrhosis | 4 | 2022 | 301 | 0.340 |
Why?
|
| Membrane Proteins | 6 | 2000 | 617 | 0.330 |
Why?
|
| Radiation Injuries | 1 | 2010 | 97 | 0.330 |
Why?
|
| Aortic Valve Stenosis | 2 | 2021 | 177 | 0.330 |
Why?
|
| Memory Disorders | 1 | 2010 | 111 | 0.320 |
Why?
|
| Tumor Cells, Cultured | 9 | 2021 | 852 | 0.320 |
Why?
|
| Aged | 17 | 2020 | 14862 | 0.310 |
Why?
|
| Algorithms | 7 | 2016 | 1196 | 0.310 |
Why?
|
| Memory | 1 | 2010 | 214 | 0.310 |
Why?
|
| Research Design | 3 | 2022 | 729 | 0.310 |
Why?
|
| Peptide Fragments | 8 | 2021 | 483 | 0.310 |
Why?
|
| Disease Models, Animal | 10 | 2022 | 2550 | 0.310 |
Why?
|
| Propanolamines | 5 | 2013 | 70 | 0.310 |
Why?
|
| Sensitivity and Specificity | 7 | 2016 | 1753 | 0.310 |
Why?
|
| Prostatic Secretory Proteins | 3 | 2012 | 3 | 0.300 |
Why?
|
| Lysophospholipids | 3 | 2019 | 209 | 0.300 |
Why?
|
| Soybean Proteins | 2 | 2018 | 11 | 0.290 |
Why?
|
| Carbohydrate Sequence | 5 | 2014 | 45 | 0.280 |
Why?
|
| Case-Control Studies | 9 | 2019 | 1553 | 0.280 |
Why?
|
| Chondroitin Sulfates | 2 | 1997 | 44 | 0.280 |
Why?
|
| Hydroxylation | 3 | 2021 | 41 | 0.280 |
Why?
|
| Histocytochemistry | 3 | 2021 | 149 | 0.270 |
Why?
|
| Reproducibility of Results | 7 | 2020 | 2077 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 446 | 0.270 |
Why?
|
| Prostatectomy | 3 | 2021 | 87 | 0.260 |
Why?
|
| Rats | 15 | 2021 | 5300 | 0.260 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 1173 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 332 | 0.260 |
Why?
|
| Adamantane | 2 | 2015 | 40 | 0.260 |
Why?
|
| Liquid Biopsy | 3 | 2020 | 6 | 0.260 |
Why?
|
| Binding Sites | 13 | 2006 | 631 | 0.250 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2005 | 13 | 0.250 |
Why?
|
| Bioterrorism | 1 | 2005 | 12 | 0.250 |
Why?
|
| Glycogen | 2 | 2022 | 27 | 0.250 |
Why?
|
| Cisplatin | 1 | 2005 | 192 | 0.240 |
Why?
|
| Peptide Hydrolases | 2 | 2021 | 82 | 0.240 |
Why?
|
| Adult | 22 | 2020 | 21403 | 0.240 |
Why?
|
| Mammography | 2 | 2022 | 310 | 0.230 |
Why?
|
| Elastin | 3 | 2021 | 116 | 0.230 |
Why?
|
| Saliva | 1 | 2005 | 142 | 0.230 |
Why?
|
| Prognosis | 6 | 2021 | 2093 | 0.230 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 267 | 0.230 |
Why?
|
| Fucose | 4 | 2019 | 25 | 0.230 |
Why?
|
| Isotope Labeling | 3 | 2019 | 30 | 0.230 |
Why?
|
| Hepatitis C, Chronic | 1 | 2005 | 86 | 0.230 |
Why?
|
| Pyridines | 2 | 2015 | 261 | 0.230 |
Why?
|
| Proline | 2 | 2020 | 52 | 0.220 |
Why?
|
| Nucleotidyltransferases | 6 | 2000 | 7 | 0.220 |
Why?
|
| Antiviral Agents | 5 | 2002 | 211 | 0.220 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2019 | 381 | 0.220 |
Why?
|
| T-Lymphocytes | 3 | 2015 | 597 | 0.220 |
Why?
|
| Thymidine | 3 | 1999 | 32 | 0.220 |
Why?
|
| Cell Proliferation | 6 | 2021 | 1174 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 68 | 0.210 |
Why?
|
| Biopsy | 2 | 2019 | 540 | 0.210 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 306 | 0.210 |
Why?
|
| Sarcoma, Ewing | 1 | 2022 | 26 | 0.210 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 481 | 0.210 |
Why?
|
| Apoptosis | 6 | 2021 | 1641 | 0.210 |
Why?
|
| Osteosarcoma | 1 | 2022 | 35 | 0.210 |
Why?
|
| Tandem Mass Spectrometry | 4 | 2020 | 139 | 0.210 |
Why?
|
| Optic Disk | 1 | 2022 | 37 | 0.210 |
Why?
|
| Ocular Hypertension | 1 | 2022 | 43 | 0.200 |
Why?
|
| Tissue Distribution | 3 | 2021 | 282 | 0.200 |
Why?
|
| Phosphotransferases (Phosphomutases) | 1 | 2021 | 2 | 0.200 |
Why?
|
| Primary Graft Dysfunction | 1 | 2021 | 12 | 0.200 |
Why?
|
| Cells, Cultured | 5 | 2021 | 2673 | 0.200 |
Why?
|
| Bone Neoplasms | 1 | 2022 | 100 | 0.200 |
Why?
|
| Mutation | 4 | 2003 | 1213 | 0.200 |
Why?
|
| Disease-Free Survival | 4 | 2020 | 349 | 0.200 |
Why?
|
| Connexin 43 | 2 | 2000 | 62 | 0.200 |
Why?
|
| Glucosamine | 1 | 2021 | 8 | 0.200 |
Why?
|
| Antigens, Neoplasm | 3 | 2017 | 132 | 0.190 |
Why?
|
| Cadherins | 1 | 2021 | 93 | 0.190 |
Why?
|
| Patient Portals | 1 | 2021 | 12 | 0.190 |
Why?
|
| Thymine Nucleotides | 2 | 1998 | 6 | 0.190 |
Why?
|
| Mevalonic Acid | 1 | 2021 | 27 | 0.190 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 86 | 0.190 |
Why?
|
| Sialic Acids | 2 | 2022 | 27 | 0.190 |
Why?
|
| Cell Death | 4 | 2012 | 329 | 0.190 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 87 | 0.190 |
Why?
|
| MicroRNAs | 2 | 2018 | 447 | 0.190 |
Why?
|
| Psychotic Disorders | 2 | 2019 | 157 | 0.190 |
Why?
|
| Uridine Diphosphate Sugars | 6 | 1997 | 8 | 0.190 |
Why?
|
| Collagen Type VIII | 1 | 2020 | 7 | 0.180 |
Why?
|
| Non-Fibrillar Collagens | 1 | 2020 | 9 | 0.180 |
Why?
|
| Collagen Type III | 1 | 2020 | 21 | 0.180 |
Why?
|
| Lung Transplantation | 1 | 2021 | 88 | 0.180 |
Why?
|
| Deoxyuridine | 4 | 1995 | 8 | 0.180 |
Why?
|
| Endometrial Neoplasms | 2 | 2014 | 69 | 0.180 |
Why?
|
| Collagen Type IV | 1 | 2020 | 28 | 0.180 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2020 | 72 | 0.180 |
Why?
|
| Staphylococcal Infections | 2 | 2012 | 156 | 0.180 |
Why?
|
| Inflammation | 3 | 2022 | 1030 | 0.180 |
Why?
|
| Fucosyltransferases | 1 | 2020 | 6 | 0.180 |
Why?
|
| Fibrillar Collagens | 1 | 2020 | 49 | 0.180 |
Why?
|
| Antigens, CD | 3 | 2015 | 230 | 0.180 |
Why?
|
| Conserved Sequence | 2 | 1998 | 67 | 0.180 |
Why?
|
| Acid Ceramidase | 3 | 2018 | 85 | 0.180 |
Why?
|
| Neoplasm Grading | 3 | 2017 | 111 | 0.180 |
Why?
|
| Autoantigens | 1 | 2020 | 91 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 7 | 2021 | 2791 | 0.170 |
Why?
|
| Acid Phosphatase | 3 | 2009 | 36 | 0.170 |
Why?
|
| Methods | 1 | 2019 | 156 | 0.170 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2020 | 39 | 0.170 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 4848 | 0.170 |
Why?
|
| HIV-1 | 2 | 1998 | 177 | 0.170 |
Why?
|
| Pancreas | 1 | 2020 | 225 | 0.170 |
Why?
|
| Collagen Type I | 1 | 2020 | 175 | 0.170 |
Why?
|
| Chromatography, Liquid | 5 | 2021 | 120 | 0.170 |
Why?
|
| Biocompatible Materials | 1 | 2021 | 247 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 174 | 0.170 |
Why?
|
| Lung | 2 | 2014 | 849 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 96 | 0.170 |
Why?
|
| Students | 3 | 2019 | 233 | 0.170 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 62 | 0.170 |
Why?
|
| Receptors, Purinergic | 1 | 2019 | 10 | 0.170 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2019 | 5 | 0.170 |
Why?
|
| CA-19-9 Antigen | 1 | 2019 | 5 | 0.170 |
Why?
|
| Sulfotransferases | 2 | 1996 | 7 | 0.170 |
Why?
|
| Body Mass Index | 1 | 2022 | 867 | 0.160 |
Why?
|
| Molecular Weight | 13 | 2011 | 358 | 0.160 |
Why?
|
| Optical Imaging | 1 | 2019 | 46 | 0.160 |
Why?
|
| Recombinant Proteins | 10 | 2006 | 742 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2021 | 304 | 0.160 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 207 | 0.160 |
Why?
|
| Gap Junctions | 1 | 1998 | 29 | 0.160 |
Why?
|
| Breast Diseases | 1 | 2018 | 40 | 0.160 |
Why?
|
| Endoplasmic Reticulum | 6 | 2021 | 148 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 179 | 0.160 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 186 | 0.160 |
Why?
|
| Rhinosporidiosis | 1 | 2018 | 7 | 0.160 |
Why?
|
| Uridine Diphosphate | 1 | 1998 | 3 | 0.160 |
Why?
|
| HIV Integrase | 1 | 1998 | 2 | 0.160 |
Why?
|
| Hexosamines | 1 | 1998 | 10 | 0.160 |
Why?
|
| Cognition | 2 | 2014 | 513 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2020 | 170 | 0.160 |
Why?
|
| Microscopy | 1 | 2018 | 64 | 0.160 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2019 | 152 | 0.150 |
Why?
|
| Photochemistry | 8 | 1996 | 46 | 0.150 |
Why?
|
| Aorta | 1 | 2019 | 316 | 0.150 |
Why?
|
| Receptors, Complement | 1 | 2018 | 58 | 0.150 |
Why?
|
| Genistein | 1 | 2018 | 26 | 0.150 |
Why?
|
| Protein Structure, Secondary | 1 | 1998 | 136 | 0.150 |
Why?
|
| Stavudine | 1 | 1997 | 1 | 0.150 |
Why?
|
| Pattern Recognition, Automated | 2 | 2008 | 70 | 0.150 |
Why?
|
| Sulfones | 3 | 1995 | 45 | 0.150 |
Why?
|
| Disease Management | 1 | 2019 | 248 | 0.150 |
Why?
|
| Carcinogenesis | 2 | 2018 | 124 | 0.150 |
Why?
|
| Health Care Costs | 1 | 2020 | 346 | 0.150 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2018 | 62 | 0.150 |
Why?
|
| Transferases | 2 | 1998 | 14 | 0.150 |
Why?
|
| Farber Lipogranulomatosis | 1 | 2017 | 5 | 0.150 |
Why?
|
| Nervous System Malformations | 1 | 2017 | 7 | 0.150 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 94 | 0.140 |
Why?
|
| Xenopus Proteins | 2 | 1998 | 31 | 0.140 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2021 | 135 | 0.140 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 9 | 1997 | 272 | 0.140 |
Why?
|
| Cell Adhesion Molecules | 2 | 2015 | 199 | 0.140 |
Why?
|
| Blotting, Western | 7 | 2016 | 954 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 468 | 0.140 |
Why?
|
| Mucin 5AC | 1 | 2016 | 3 | 0.140 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2009 | 50 | 0.140 |
Why?
|
| Drug-Seeking Behavior | 1 | 2019 | 213 | 0.140 |
Why?
|
| Mice, Knockout | 5 | 2021 | 1692 | 0.140 |
Why?
|
| Gaucher Disease | 1 | 2017 | 60 | 0.140 |
Why?
|
| Atherosclerosis | 1 | 2019 | 204 | 0.140 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2018 | 105 | 0.140 |
Why?
|
| Young Adult | 6 | 2018 | 5717 | 0.140 |
Why?
|
| Colitis | 1 | 2018 | 156 | 0.140 |
Why?
|
| Central Nervous System | 1 | 2017 | 107 | 0.140 |
Why?
|
| Adolescent Behavior | 1 | 2019 | 264 | 0.140 |
Why?
|
| Endothelial Cells | 1 | 2019 | 384 | 0.140 |
Why?
|
| Hippocampus | 1 | 2019 | 471 | 0.140 |
Why?
|
| Cell Line | 7 | 2018 | 1752 | 0.140 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 807 | 0.130 |
Why?
|
| Aspartic Acid | 1 | 1996 | 65 | 0.130 |
Why?
|
| Matrix Metalloproteinases | 1 | 2017 | 223 | 0.130 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 596 | 0.130 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 800 | 0.130 |
Why?
|
| Receptors, CXCR3 | 1 | 2015 | 16 | 0.130 |
Why?
|
| Keratan Sulfate | 1 | 1995 | 12 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 581 | 0.130 |
Why?
|
| Nephritis | 1 | 2015 | 37 | 0.130 |
Why?
|
| Transplantation, Heterologous | 1 | 2015 | 122 | 0.130 |
Why?
|
| Job Satisfaction | 1 | 2016 | 62 | 0.130 |
Why?
|
| Mutagenesis, Site-Directed | 5 | 2006 | 204 | 0.130 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 333 | 0.130 |
Why?
|
| Hydrolysis | 2 | 2014 | 144 | 0.130 |
Why?
|
| Deoxyuracil Nucleotides | 1 | 1995 | 9 | 0.130 |
Why?
|
| Comorbidity | 3 | 2020 | 1426 | 0.130 |
Why?
|
| Workplace | 1 | 2016 | 75 | 0.130 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2015 | 33 | 0.130 |
Why?
|
| Oxidative Stress | 1 | 2019 | 718 | 0.130 |
Why?
|
| Lipofuscin | 1 | 2015 | 43 | 0.130 |
Why?
|
| Oxidoreductases | 1 | 2015 | 117 | 0.130 |
Why?
|
| Stress, Psychological | 2 | 2019 | 824 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2018 | 332 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 126 | 0.120 |
Why?
|
| Kinetics | 12 | 2006 | 1047 | 0.120 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2014 | 9 | 0.120 |
Why?
|
| Paraffin | 1 | 2014 | 7 | 0.120 |
Why?
|
| Adenoma | 1 | 2016 | 132 | 0.120 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2015 | 106 | 0.120 |
Why?
|
| Cocaine | 1 | 2019 | 555 | 0.120 |
Why?
|
| Cocaine-Related Disorders | 1 | 2019 | 504 | 0.120 |
Why?
|
| Retinoids | 1 | 2015 | 122 | 0.120 |
Why?
|
| Exercise | 1 | 2020 | 658 | 0.120 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 65 | 0.120 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 188 | 0.120 |
Why?
|
| Ethanol | 2 | 2018 | 893 | 0.120 |
Why?
|
| Performance-Enhancing Substances | 1 | 2014 | 2 | 0.120 |
Why?
|
| Wakefulness-Promoting Agents | 1 | 2014 | 6 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2020 | 2358 | 0.120 |
Why?
|
| Biological Specimen Banks | 1 | 2014 | 38 | 0.120 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2015 | 145 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2014 | 168 | 0.110 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 454 | 0.110 |
Why?
|
| Epithelial Cells | 3 | 2018 | 431 | 0.110 |
Why?
|
| Databases, Protein | 2 | 2012 | 49 | 0.110 |
Why?
|
| Cryopreservation | 1 | 2014 | 103 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2019 | 258 | 0.110 |
Why?
|
| Radiation Tolerance | 1 | 2013 | 30 | 0.110 |
Why?
|
| Benzhydryl Compounds | 1 | 2014 | 62 | 0.110 |
Why?
|
| Sphingosine | 1 | 2015 | 315 | 0.110 |
Why?
|
| Intention | 1 | 2014 | 80 | 0.110 |
Why?
|
| Click Chemistry | 1 | 2013 | 7 | 0.110 |
Why?
|
| Glutathione Transferase | 1 | 2014 | 166 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2013 | 35 | 0.110 |
Why?
|
| Alkynes | 1 | 2013 | 12 | 0.110 |
Why?
|
| Genomics | 1 | 2014 | 168 | 0.110 |
Why?
|
| Saccharomyces cerevisiae | 2 | 1992 | 173 | 0.110 |
Why?
|
| Hypertension | 1 | 2022 | 1535 | 0.110 |
Why?
|
| Amides | 1 | 2013 | 86 | 0.110 |
Why?
|
| Streptococcus pyogenes | 1 | 1992 | 20 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 331 | 0.110 |
Why?
|
| Lupus Nephritis | 1 | 2014 | 193 | 0.110 |
Why?
|
| Proteinuria | 1 | 2013 | 136 | 0.110 |
Why?
|
| Swine | 8 | 1998 | 672 | 0.110 |
Why?
|
| Tyrosine | 2 | 1999 | 196 | 0.100 |
Why?
|
| Tissue Donors | 1 | 2014 | 195 | 0.100 |
Why?
|
| Adenosine Triphosphate | 5 | 1998 | 314 | 0.100 |
Why?
|
| Diethylnitrosamine | 3 | 2018 | 10 | 0.100 |
Why?
|
| Phosphorus Radioisotopes | 7 | 1998 | 29 | 0.100 |
Why?
|
| Palliative Care | 2 | 2012 | 271 | 0.100 |
Why?
|
| Histocompatibility Antigens | 1 | 2012 | 12 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3259 | 0.100 |
Why?
|
| Complement C4 | 1 | 2012 | 15 | 0.100 |
Why?
|
| Mannosyltransferases | 1 | 1992 | 4 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 370 | 0.100 |
Why?
|
| Chromatography, Ion Exchange | 3 | 2009 | 73 | 0.100 |
Why?
|
| Immune Evasion | 1 | 2012 | 19 | 0.100 |
Why?
|
| Kallikreins | 1 | 2013 | 323 | 0.100 |
Why?
|
| Cytokines | 2 | 2022 | 866 | 0.100 |
Why?
|
| Learning | 1 | 2014 | 186 | 0.100 |
Why?
|
| Cations | 1 | 2011 | 51 | 0.100 |
Why?
|
| Fungal Proteins | 1 | 1992 | 37 | 0.100 |
Why?
|
| Cell Membrane | 6 | 1998 | 525 | 0.100 |
Why?
|
| Depression | 1 | 2019 | 943 | 0.100 |
Why?
|
| Lewis X Antigen | 1 | 2011 | 2 | 0.100 |
Why?
|
| Monosaccharides | 1 | 2011 | 4 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 492 | 0.100 |
Why?
|
| Quality of Life | 1 | 2020 | 1515 | 0.100 |
Why?
|
| Boron Compounds | 1 | 2011 | 21 | 0.100 |
Why?
|
| Body Fluids | 2 | 2009 | 41 | 0.100 |
Why?
|
| Cross-Linking Reagents | 1 | 1992 | 80 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2021 | 2083 | 0.100 |
Why?
|
| Child Health Services | 1 | 2012 | 50 | 0.100 |
Why?
|
| Global Health | 1 | 2012 | 136 | 0.100 |
Why?
|
| Sialoglycoproteins | 1 | 2011 | 24 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 300 | 0.100 |
Why?
|
| Complement Activation | 1 | 2012 | 145 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 2223 | 0.090 |
Why?
|
| Empathy | 1 | 2011 | 45 | 0.090 |
Why?
|
| Structure-Activity Relationship | 2 | 2002 | 420 | 0.090 |
Why?
|
| Adolescent | 8 | 2021 | 8912 | 0.090 |
Why?
|
| Personality Inventory | 1 | 2011 | 197 | 0.090 |
Why?
|
| Transfection | 4 | 2000 | 782 | 0.090 |
Why?
|
| Base Sequence | 5 | 1998 | 1015 | 0.090 |
Why?
|
| Risk Assessment | 5 | 2020 | 2007 | 0.090 |
Why?
|
| Bacteria, Aerobic | 1 | 2009 | 7 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2011 | 159 | 0.090 |
Why?
|
| Paclitaxel | 3 | 2014 | 140 | 0.090 |
Why?
|
| Models, Molecular | 3 | 2002 | 546 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2010 | 219 | 0.090 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2009 | 34 | 0.090 |
Why?
|
| Caspases | 2 | 2000 | 194 | 0.090 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2009 | 29 | 0.080 |
Why?
|
| Pain, Intractable | 1 | 2009 | 28 | 0.080 |
Why?
|
| Prostatic Hyperplasia | 1 | 2009 | 25 | 0.080 |
Why?
|
| Child | 5 | 2022 | 6405 | 0.080 |
Why?
|
| Caspase 3 | 2 | 2000 | 233 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 786 | 0.080 |
Why?
|
| Interpersonal Relations | 1 | 2011 | 209 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2010 | 248 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 3 | 2019 | 532 | 0.080 |
Why?
|
| Rats, Wistar | 1 | 2010 | 371 | 0.080 |
Why?
|
| ras Proteins | 1 | 2010 | 102 | 0.080 |
Why?
|
| Carcinoma in Situ | 1 | 2009 | 47 | 0.080 |
Why?
|
| Myeloid Cells | 1 | 2009 | 57 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 1 | 2010 | 247 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 767 | 0.080 |
Why?
|
| Cattle | 4 | 2000 | 475 | 0.080 |
Why?
|
| Aging | 2 | 2015 | 911 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2009 | 163 | 0.080 |
Why?
|
| United States | 3 | 2020 | 7367 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2020 | 7277 | 0.070 |
Why?
|
| Mitochondria | 1 | 2012 | 643 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2009 | 201 | 0.070 |
Why?
|
| Macromolecular Substances | 5 | 1994 | 122 | 0.070 |
Why?
|
| Genes, BRCA1 | 2 | 2004 | 47 | 0.070 |
Why?
|
| Radiation Dosage | 1 | 2010 | 419 | 0.070 |
Why?
|
| Molecular Structure | 3 | 1993 | 397 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 1140 | 0.070 |
Why?
|
| Deoxycytidine | 2 | 2012 | 83 | 0.070 |
Why?
|
| Phosphorylation | 5 | 2000 | 1200 | 0.070 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2005 | 1 | 0.070 |
Why?
|
| Phenylalanine | 1 | 2006 | 22 | 0.070 |
Why?
|
| Photoaffinity Labels | 3 | 2006 | 7 | 0.070 |
Why?
|
| Computational Biology | 1 | 2007 | 190 | 0.070 |
Why?
|
| 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid | 3 | 1996 | 4 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 546 | 0.070 |
Why?
|
| Time Factors | 2 | 2017 | 4655 | 0.070 |
Why?
|
| Cell Count | 2 | 2009 | 248 | 0.070 |
Why?
|
| Hysterectomy | 1 | 2005 | 64 | 0.070 |
Why?
|
| Alkylating Agents | 2 | 2016 | 15 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2019 | 714 | 0.060 |
Why?
|
| Mice, Inbred MRL lpr | 2 | 2015 | 118 | 0.060 |
Why?
|
| Decision Trees | 1 | 2005 | 74 | 0.060 |
Why?
|
| Immunoblotting | 2 | 2015 | 254 | 0.060 |
Why?
|
| BRCA1 Protein | 1 | 2004 | 30 | 0.060 |
Why?
|
| Viral Proteins | 2 | 1996 | 150 | 0.060 |
Why?
|
| Cell Survival | 2 | 2014 | 901 | 0.060 |
Why?
|
| Glycolipids | 2 | 1995 | 20 | 0.060 |
Why?
|
| Influenza Vaccines | 1 | 2005 | 56 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2005 | 79 | 0.060 |
Why?
|
| Biopsy, Needle | 3 | 2014 | 191 | 0.060 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 2 | 1996 | 15 | 0.060 |
Why?
|
| Analgesics, Opioid | 1 | 2009 | 498 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 129 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2004 | 104 | 0.060 |
Why?
|
| Hepatitis B | 1 | 2004 | 42 | 0.060 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 2 | 1994 | 5 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 129 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2004 | 130 | 0.060 |
Why?
|
| Indicators and Reagents | 2 | 1994 | 63 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 507 | 0.060 |
Why?
|
| Peptide Mapping | 2 | 2008 | 39 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2004 | 231 | 0.050 |
Why?
|
| Bystander Effect | 1 | 2002 | 10 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 2800 | 0.050 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2002 | 24 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2013 | 294 | 0.050 |
Why?
|
| Drug Resistance, Multiple | 1 | 2002 | 56 | 0.050 |
Why?
|
| Sphingomyelins | 1 | 2022 | 106 | 0.050 |
Why?
|
| Diet, Western | 1 | 2022 | 17 | 0.050 |
Why?
|
| Universities | 2 | 2016 | 191 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2002 | 312 | 0.050 |
Why?
|
| Protein Binding | 2 | 2013 | 1027 | 0.050 |
Why?
|
| Lasers | 1 | 2021 | 61 | 0.050 |
Why?
|
| Obesity | 1 | 2009 | 1076 | 0.050 |
Why?
|
| Lafora Disease | 1 | 2021 | 1 | 0.050 |
Why?
|
| Glycogenolysis | 1 | 2021 | 1 | 0.050 |
Why?
|
| Glycogen Synthase | 1 | 2021 | 5 | 0.050 |
Why?
|
| Chromatography, DEAE-Cellulose | 3 | 1996 | 14 | 0.050 |
Why?
|
| Ischemia | 1 | 2022 | 229 | 0.050 |
Why?
|
| Microtomy | 1 | 2020 | 11 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 63 | 0.050 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 1992 | 79 | 0.050 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2022 | 183 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 160 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2020 | 73 | 0.050 |
Why?
|
| Retina | 1 | 2022 | 252 | 0.050 |
Why?
|
| DNA Primers | 2 | 1998 | 302 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2021 | 238 | 0.050 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2000 | 4 | 0.050 |
Why?
|
| Staurosporine | 1 | 2000 | 19 | 0.050 |
Why?
|
| Butyrates | 1 | 2000 | 14 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 160 | 0.040 |
Why?
|
| Camptothecin | 1 | 2000 | 39 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 5731 | 0.040 |
Why?
|
| bcl-X Protein | 1 | 2000 | 36 | 0.040 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2020 | 24 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2008 | 3705 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 38 | 0.040 |
Why?
|
| Uridine Diphosphate Galactose | 2 | 1996 | 2 | 0.040 |
Why?
|
| Alkaloids | 1 | 2000 | 40 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 1999 | 124 | 0.040 |
Why?
|
| Metalloendopeptidases | 2 | 1998 | 67 | 0.040 |
Why?
|
| Glutamine | 1 | 1999 | 45 | 0.040 |
Why?
|
| Smoking | 1 | 2008 | 1452 | 0.040 |
Why?
|
| Research | 1 | 2021 | 214 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 238 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2000 | 289 | 0.040 |
Why?
|
| Psychotherapy, Brief | 1 | 1999 | 30 | 0.040 |
Why?
|
| Magnesium | 2 | 1996 | 110 | 0.040 |
Why?
|
| Uridine Diphosphate Xylose | 2 | 1997 | 2 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2021 | 434 | 0.040 |
Why?
|
| Fibrosis | 1 | 2021 | 371 | 0.040 |
Why?
|
| Thinking | 1 | 2019 | 30 | 0.040 |
Why?
|
| Antibodies | 1 | 2019 | 241 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 307 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 213 | 0.040 |
Why?
|
| Aspergillus fumigatus | 1 | 2018 | 27 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 1990 | 765 | 0.040 |
Why?
|
| Dideoxynucleotides | 1 | 1998 | 3 | 0.040 |
Why?
|
| Tritium | 1 | 1998 | 101 | 0.040 |
Why?
|
| Pasteurella multocida | 1 | 1998 | 6 | 0.040 |
Why?
|
| Brain Mapping | 1 | 2021 | 532 | 0.040 |
Why?
|
| Hydrogen Bonding | 1 | 1998 | 67 | 0.040 |
Why?
|
| Pentosyltransferases | 1 | 1997 | 1 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2015 | 489 | 0.040 |
Why?
|
| Guanosine Triphosphate | 2 | 1998 | 65 | 0.040 |
Why?
|
| Neomycin | 1 | 1998 | 56 | 0.040 |
Why?
|
| Biological Transport | 2 | 1996 | 210 | 0.040 |
Why?
|
| Complement C3 | 1 | 2018 | 101 | 0.040 |
Why?
|
| Self Administration | 1 | 2019 | 419 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2020 | 146 | 0.040 |
Why?
|
| Lysine | 1 | 1998 | 96 | 0.040 |
Why?
|
| Extinction, Psychological | 1 | 2019 | 240 | 0.040 |
Why?
|
| Conditioning, Operant | 1 | 2019 | 241 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2018 | 68 | 0.040 |
Why?
|
| Plant Proteins | 1 | 1997 | 48 | 0.040 |
Why?
|
| Zalcitabine | 1 | 1997 | 4 | 0.040 |
Why?
|
| Nucleosides | 1 | 1997 | 9 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2018 | 88 | 0.040 |
Why?
|
| Health Status | 1 | 2020 | 429 | 0.040 |
Why?
|
| Multigene Family | 1 | 2018 | 93 | 0.040 |
Why?
|
| Allergens | 1 | 1997 | 54 | 0.040 |
Why?
|
| beta Catenin | 1 | 2018 | 73 | 0.040 |
Why?
|
| Virus Replication | 1 | 1998 | 104 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2018 | 188 | 0.040 |
Why?
|
| Growth Inhibitors | 1 | 1997 | 33 | 0.040 |
Why?
|
| Acyclovir | 1 | 1997 | 38 | 0.040 |
Why?
|
| Hyaluronan Synthases | 2 | 1998 | 21 | 0.040 |
Why?
|
| Binding, Competitive | 2 | 1995 | 165 | 0.040 |
Why?
|
| Sequence Alignment | 3 | 2006 | 165 | 0.040 |
Why?
|
| Hydroxyurea | 1 | 1997 | 57 | 0.040 |
Why?
|
| Isoenzymes | 2 | 1996 | 308 | 0.040 |
Why?
|
| Cerebrum | 1 | 2017 | 20 | 0.040 |
Why?
|
| Heterografts | 1 | 2017 | 70 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 536 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2017 | 167 | 0.040 |
Why?
|
| Computer Simulation | 2 | 1998 | 706 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2021 | 3187 | 0.040 |
Why?
|
| Homozygote | 1 | 2017 | 119 | 0.040 |
Why?
|
| Hydrocephalus | 1 | 2017 | 40 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2019 | 252 | 0.040 |
Why?
|
| Cloning, Molecular | 4 | 2000 | 357 | 0.040 |
Why?
|
| Autoradiography | 3 | 1996 | 94 | 0.040 |
Why?
|
| Acetylgalactosamine | 1 | 1996 | 10 | 0.030 |
Why?
|
| Heart | 1 | 2021 | 850 | 0.030 |
Why?
|
| Uridine Diphosphate N-Acetylgalactosamine | 1 | 1996 | 1 | 0.030 |
Why?
|
| Uridine Diphosphate N-Acetylglucosamine | 1 | 1996 | 2 | 0.030 |
Why?
|
| Liposarcoma, Myxoid | 1 | 2016 | 5 | 0.030 |
Why?
|
| Salicylamides | 1 | 1996 | 18 | 0.030 |
Why?
|
| Thymidine Monophosphate | 1 | 1996 | 5 | 0.030 |
Why?
|
| Leiomyosarcoma | 1 | 2016 | 17 | 0.030 |
Why?
|
| UTP-Glucose-1-Phosphate Uridylyltransferase | 1 | 1996 | 1 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2016 | 63 | 0.030 |
Why?
|
| Mycobacterium | 1 | 1996 | 12 | 0.030 |
Why?
|
| Antigens | 1 | 2016 | 90 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2014 | 1040 | 0.030 |
Why?
|
| Arylsulfotransferase | 1 | 1996 | 2 | 0.030 |
Why?
|
| Cerebellum | 1 | 2017 | 103 | 0.030 |
Why?
|
| Carrier Proteins | 2 | 1996 | 597 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1997 | 1745 | 0.030 |
Why?
|
| Southwestern United States | 1 | 2016 | 5 | 0.030 |
Why?
|
| Behavior, Addictive | 1 | 2019 | 317 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 1997 | 346 | 0.030 |
Why?
|
| Lymphocytes | 1 | 1997 | 228 | 0.030 |
Why?
|
| DNA, Viral | 1 | 1996 | 114 | 0.030 |
Why?
|
| Chemokine CXCL9 | 1 | 2015 | 8 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 1996 | 66 | 0.030 |
Why?
|
| Personnel Turnover | 1 | 2016 | 14 | 0.030 |
Why?
|
| Nasal Polyps | 1 | 2018 | 184 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 21 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 615 | 0.030 |
Why?
|
| Sulfates | 1 | 1995 | 28 | 0.030 |
Why?
|
| Macaca | 1 | 2015 | 24 | 0.030 |
Why?
|
| Lactosylceramides | 1 | 2015 | 27 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 118 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1619 | 0.030 |
Why?
|
| Myocardium | 1 | 2021 | 1204 | 0.030 |
Why?
|
| Archaea | 1 | 1995 | 7 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 282 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 209 | 0.030 |
Why?
|
| Carboxy-Lyases | 1 | 1995 | 5 | 0.030 |
Why?
|
| Ribonucleotides | 1 | 1995 | 26 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2455 | 0.030 |
Why?
|
| Dependovirus | 1 | 1995 | 34 | 0.030 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 1995 | 54 | 0.030 |
Why?
|
| HIV | 1 | 1995 | 56 | 0.030 |
Why?
|
| Point Mutation | 1 | 1995 | 97 | 0.030 |
Why?
|
| Carboplatin | 1 | 2014 | 59 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2014 | 34 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2014 | 19 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 1995 | 65 | 0.030 |
Why?
|
| Urinalysis | 1 | 2014 | 27 | 0.030 |
Why?
|
| Tissue Banks | 1 | 2014 | 13 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2014 | 69 | 0.030 |
Why?
|
| Chickens | 1 | 1995 | 232 | 0.030 |
Why?
|
| Infant | 1 | 2021 | 2891 | 0.030 |
Why?
|
| Genetic Research | 1 | 2014 | 16 | 0.030 |
Why?
|
| Lithocholic Acid | 1 | 1994 | 1 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2014 | 48 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2014 | 114 | 0.030 |
Why?
|
| Gene Expression | 2 | 2013 | 770 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 62 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2014 | 51 | 0.030 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1994 | 31 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1995 | 120 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 1033 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2014 | 81 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2017 | 470 | 0.030 |
Why?
|
| Cryoprotective Agents | 1 | 2014 | 31 | 0.030 |
Why?
|
| London | 1 | 2014 | 12 | 0.030 |
Why?
|
| Protein Stability | 1 | 2014 | 90 | 0.030 |
Why?
|
| RNA Stability | 1 | 2014 | 55 | 0.030 |
Why?
|
| Fabaceae | 1 | 1994 | 12 | 0.030 |
Why?
|
| Multilingualism | 1 | 2014 | 14 | 0.030 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 2013 | 3 | 0.030 |
Why?
|
| Military Personnel | 1 | 2016 | 221 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2013 | 10 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 947 | 0.030 |
Why?
|
| Learning Curve | 1 | 2014 | 20 | 0.030 |
Why?
|
| Software | 1 | 2016 | 418 | 0.030 |
Why?
|
| Intelligence | 1 | 2014 | 45 | 0.030 |
Why?
|
| Guanosine Diphosphate Mannose | 1 | 1993 | 1 | 0.030 |
Why?
|
| Guanosine Diphosphate Sugars | 1 | 1993 | 1 | 0.030 |
Why?
|
| Plants, Medicinal | 1 | 1994 | 43 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 151 | 0.030 |
Why?
|
| Trust | 1 | 2014 | 75 | 0.030 |
Why?
|
| Rabbits | 2 | 1996 | 509 | 0.030 |
Why?
|
| Models, Animal | 1 | 2014 | 252 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 89 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2013 | 71 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2013 | 61 | 0.030 |
Why?
|
| Motor Activity | 1 | 2017 | 621 | 0.030 |
Why?
|
| Glucosides | 1 | 1993 | 16 | 0.030 |
Why?
|
| Bile Acids and Salts | 1 | 1993 | 19 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2013 | 119 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 2014 | 79 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1330 | 0.030 |
Why?
|
| Mental Health | 1 | 2016 | 278 | 0.030 |
Why?
|
| Hospitalization | 1 | 1999 | 978 | 0.030 |
Why?
|
| Informed Consent | 1 | 2014 | 127 | 0.030 |
Why?
|
| Laboratories | 1 | 2013 | 44 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2012 | 13 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 567 | 0.030 |
Why?
|
| Protein Deglycase DJ-1 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Exonucleases | 1 | 2012 | 5 | 0.030 |
Why?
|
| Exoribonucleases | 1 | 2012 | 6 | 0.030 |
Why?
|
| Cytosol | 3 | 1998 | 123 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2014 | 447 | 0.030 |
Why?
|
| 14-3-3 Proteins | 1 | 2012 | 12 | 0.030 |
Why?
|
| Lymphoma | 1 | 1993 | 116 | 0.030 |
Why?
|
| Cytochromes c | 1 | 2012 | 75 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 35 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 226 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 420 | 0.030 |
Why?
|
| Minority Groups | 1 | 2014 | 197 | 0.030 |
Why?
|
| Spectrum Analysis | 1 | 2012 | 81 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2012 | 59 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2012 | 66 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 77 | 0.030 |
Why?
|
| Diet | 1 | 2016 | 514 | 0.030 |
Why?
|
| Detergents | 1 | 1992 | 34 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2012 | 93 | 0.030 |
Why?
|
| Endopeptidases | 1 | 1992 | 52 | 0.030 |
Why?
|
| Complement C4b-Binding Protein | 1 | 2012 | 1 | 0.030 |
Why?
|
| Species Specificity | 1 | 1992 | 303 | 0.030 |
Why?
|
| Transglutaminases | 1 | 2012 | 67 | 0.030 |
Why?
|
| Salicylates | 2 | 2006 | 22 | 0.030 |
Why?
|
| Cricetinae | 3 | 1998 | 262 | 0.030 |
Why?
|
| Uridine Diphosphate Glucose Dehydrogenase | 1 | 1991 | 3 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 499 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 1991 | 104 | 0.020 |
Why?
|
| Hymecromone | 2 | 2006 | 4 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2012 | 128 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 258 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2012 | 90 | 0.020 |
Why?
|
| Chromatography, Gel | 3 | 1996 | 79 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 216 | 0.020 |
Why?
|
| Neurons | 1 | 2017 | 881 | 0.020 |
Why?
|
| Integrin beta1 | 1 | 2011 | 48 | 0.020 |
Why?
|
| Ultrafiltration | 1 | 2011 | 35 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 561 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2011 | 54 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 1995 | 700 | 0.020 |
Why?
|
| Anger | 1 | 2011 | 47 | 0.020 |
Why?
|
| Phosphoglucomutase | 1 | 1990 | 1 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2011 | 69 | 0.020 |
Why?
|
| United Kingdom | 1 | 2011 | 152 | 0.020 |
Why?
|
| Phosphotransferases | 1 | 1990 | 16 | 0.020 |
Why?
|
| Escherichia coli | 3 | 2000 | 368 | 0.020 |
Why?
|
| Polyisoprenyl Phosphate Monosaccharides | 1 | 1990 | 1 | 0.020 |
Why?
|
| Polyisoprenyl Phosphate Sugars | 1 | 1990 | 1 | 0.020 |
Why?
|
| Gluconacetobacter xylinus | 1 | 1990 | 1 | 0.020 |
Why?
|
| Arabidopsis Proteins | 1 | 1990 | 13 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2011 | 201 | 0.020 |
Why?
|
| Motivation | 1 | 2014 | 561 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 274 | 0.020 |
Why?
|
| Plants | 1 | 1990 | 26 | 0.020 |
Why?
|
| Vegetables | 1 | 1990 | 76 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1738 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinase 2 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Enzyme Inhibitors | 3 | 1998 | 659 | 0.020 |
Why?
|
| Schizosaccharomyces pombe Proteins | 1 | 1990 | 31 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2009 | 12 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1989 | 62 | 0.020 |
Why?
|
| Chemistry | 1 | 1989 | 45 | 0.020 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2009 | 17 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2011 | 132 | 0.020 |
Why?
|
| Syndrome | 1 | 2010 | 255 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1864 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2009 | 46 | 0.020 |
Why?
|
| Microsomes | 3 | 1997 | 31 | 0.020 |
Why?
|
| Morphine | 1 | 2009 | 76 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 100 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1851 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 334 | 0.020 |
Why?
|
| Hexosephosphates | 2 | 1998 | 4 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 235 | 0.020 |
Why?
|
| Phenol | 1 | 2006 | 6 | 0.020 |
Why?
|
| Nitrophenols | 1 | 2006 | 14 | 0.020 |
Why?
|
| Catalysis | 2 | 1998 | 123 | 0.020 |
Why?
|
| Entropy | 1 | 2006 | 16 | 0.020 |
Why?
|
| Serum | 1 | 2006 | 24 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2006 | 29 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2005 | 49 | 0.020 |
Why?
|
| Calibration | 1 | 2006 | 73 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2006 | 55 | 0.020 |
Why?
|
| Premenopause | 1 | 2005 | 57 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 245 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1996 | 618 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 579 | 0.020 |
Why?
|
| Genetic Vectors | 2 | 1997 | 312 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 159 | 0.010 |
Why?
|
| Mastectomy | 1 | 2004 | 57 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 329 | 0.010 |
Why?
|
| Deoxycholic Acid | 2 | 1993 | 4 | 0.010 |
Why?
|
| Amyloid | 1 | 2004 | 39 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 792 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2004 | 163 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2005 | 7029 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 567 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1995 | 376 | 0.010 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2003 | 53 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2004 | 275 | 0.010 |
Why?
|
| Intracellular Membranes | 2 | 1990 | 86 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2000 | 47 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2000 | 137 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2000 | 251 | 0.010 |
Why?
|
| Episode of Care | 1 | 1999 | 12 | 0.010 |
Why?
|
| Guanosine Diphosphate Fucose | 1 | 1998 | 2 | 0.010 |
Why?
|
| CHO Cells | 1 | 1998 | 161 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 1998 | 12 | 0.010 |
Why?
|
| Arabinose | 1 | 1998 | 3 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 1998 | 40 | 0.010 |
Why?
|
| Soybeans | 1 | 1997 | 11 | 0.010 |
Why?
|
| Dogs | 1 | 1998 | 490 | 0.010 |
Why?
|
| Acute Disease | 1 | 1999 | 658 | 0.010 |
Why?
|
| Metals | 1 | 1998 | 100 | 0.010 |
Why?
|
| Moloney murine leukemia virus | 1 | 1997 | 13 | 0.010 |
Why?
|
| Methylmannosides | 1 | 1996 | 2 | 0.010 |
Why?
|
| Metalloproteins | 1 | 1996 | 3 | 0.010 |
Why?
|
| Cathepsin D | 1 | 1996 | 13 | 0.010 |
Why?
|
| Tartrate-Resistant Acid Phosphatase | 1 | 1996 | 22 | 0.010 |
Why?
|
| Ribonucleases | 1 | 1996 | 25 | 0.010 |
Why?
|
| Manganese | 1 | 1996 | 26 | 0.010 |
Why?
|
| Probenecid | 1 | 1996 | 10 | 0.010 |
Why?
|
| Sulfhydryl Reagents | 1 | 1996 | 6 | 0.010 |
Why?
|
| Cations, Divalent | 1 | 1996 | 27 | 0.010 |
Why?
|
| Cell Separation | 1 | 1997 | 132 | 0.010 |
Why?
|
| Furosemide | 1 | 1996 | 45 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1996 | 134 | 0.010 |
Why?
|
| Enzyme Stability | 1 | 1996 | 30 | 0.010 |
Why?
|
| Recurrence | 1 | 1999 | 948 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 1997 | 84 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 1997 | 92 | 0.010 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1997 | 132 | 0.010 |
Why?
|
| Databases, Factual | 1 | 1998 | 622 | 0.010 |
Why?
|
| Lipopeptides | 1 | 1995 | 7 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1995 | 41 | 0.010 |
Why?
|
| Maltose-Binding Proteins | 1 | 1995 | 2 | 0.010 |
Why?
|
| Heparin | 1 | 1996 | 205 | 0.010 |
Why?
|
| Triticum | 1 | 1995 | 14 | 0.010 |
Why?
|
| Naphthols | 1 | 1995 | 5 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1999 | 1342 | 0.010 |
Why?
|
| DNA Helicases | 1 | 1995 | 64 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1995 | 152 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1996 | 791 | 0.010 |
Why?
|
| Hydroxyapatites | 1 | 1993 | 10 | 0.010 |
Why?
|
| Micelles | 1 | 1993 | 43 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1993 | 34 | 0.010 |
Why?
|
| Glucosidases | 1 | 1993 | 4 | 0.010 |
Why?
|
| Chromatography | 1 | 1993 | 47 | 0.010 |
Why?
|
| Glucuronidase | 1 | 1993 | 11 | 0.010 |
Why?
|
| Durapatite | 1 | 1993 | 33 | 0.010 |
Why?
|
| Phospholipids | 1 | 1993 | 108 | 0.010 |
Why?
|
| Calcium | 1 | 1996 | 929 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1993 | 362 | 0.010 |
Why?
|
| Isoelectric Point | 1 | 1990 | 9 | 0.010 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1990 | 14 | 0.010 |
Why?
|